Page 45 - 51 the significance--29.2_opt
P. 45
glycaemia, weight gain, allergic skin reactions, liver function problems,
abdominal pain, nausea, diarrhoea, vomiting, constipation and visual
disturbances.
17
Repaglinide does not require a dose adjustment in T2DM patients with
Stage 3-5 CKD or those who are on dialysis (Table 1). Indeed, the renal
18
clearance of repaglinide is <10%. Nateglinide on the other hand should
be avoided in Stage 3-5 CKD and in patients who are on dialysis (Table 1) ,
18
since it is metabolised into active metabolites and could therefore ex-
pose patients with CKD to the risk of severe hypoglycaemia.
Figure 2. The mode of action of secretagogues (sulphonylureas and meglitinides).
45
